Figure 3.
Factors reducing adherence to capecitabine on XELOX treatment as adjuvant therapy (n = 2,103). Factors reducing adherence to capecitabine during cycles 1–8.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.